Brief: Revive to start Phase 2b trial in gout after access to required capital
10/05/2016 12:04
May 10 (Reuters) - Revive Therapeutics Ltd RVV.V
* Says will start its Phase 2B trial in gout when it has
access to capital necessary to fund trial
* Over last several months, has taken necessary steps to
reduce its monthly cash burn rate and streamline its operations
Source text for Eikon: ID:nMKWBpdjZa
Further company coverage: RVV.V
(Bengaluru Newsroom: +1 646 223 8780)
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure